ID: ALA3321818

Max Phase: Preclinical

Molecular Formula: C25H16F4N6O2

Molecular Weight: 508.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)c1c(N)n(-c2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2F)c2nc3ccccc3nc12

Standard InChI:  InChI=1S/C25H16F4N6O2/c26-15-9-8-12(24(37)32-14-5-3-4-13(11-14)25(27,28)29)10-18(15)35-21(30)19(22(31)36)20-23(35)34-17-7-2-1-6-16(17)33-20/h1-11H,30H2,(H2,31,36)(H,32,37)

Standard InChI Key:  BKTPVMHDDWZFJE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 508.44

Molecular Weight (Monoisotopic): 508.1271

AlogP: 4.67

#Rotatable Bonds: 4

Polar Surface Area: 128.92

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.84

CX Basic pKa: 0.78

CX LogP: 4.91

CX LogD: 4.91

Aromatic Rings: 5

Heavy Atoms: 37

QED Weighted: 0.30

Np Likeness Score: -1.73

References

1. Unzue A, Dong J, Lafleur K, Zhao H, Frugier E, Caflisch A, Nevado C..  (2014)  Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.,  57  (15): [PMID:25076195] [10.1021/jm5009242]

Source

Source(1):

• Scientific Literature